If you are ready to simplify and reduce the time it takes to connect with reporters for the research and innovation at your institution, we are here for you.
Inside Tarik Dickens’ lab at the FAMU-FSU College of Engineering, researchers are fine-tuning the tools used in 3D printing, helping to create better, stronger materials for a wide variety of applications.
Researchers at the Department of Energy’s Oak Ridge National Laboratory, in collaboration with three other national labs, have developed a free online platform to help utilities understand how solar energy projects will affect the operation of their power systems. This capability can increase utilities’ confidence in expanding their solar portfolios, protecting reliable delivery of electricity while supporting U.S. efforts to slow climate change.
Nearly 50 presentations by researchers and clinicians from Yale Cancer Center (YCC) at Yale School of Medicine will be among the more than 5,000 abstracts available during the annual meeting of the American Society of Clinical Oncology (ASCO) May 31 to June 4 in Chicago, Ill. This year's meeting, themed “The Art and Science of Cancer Care: From Comfort to Cure” will include over 200 sessions.
Recently, exciting new paper unveils the potential of biosurfactants—natural compounds produced by microbes—to significantly improve the preservation of meat products. This innovative approach could replace synthetic chemicals, enhancing food safety and quality.
Argonne’s Aurora system has officially entered the exascale era with its latest submission to the Top500 list of the world’s most powerful supercomputers.
Actually, sometimes consumers don’t want to talk to a real person when they’re shopping online, a new study suggests. In fact, what they really want is a chatbot that makes it clear that it is not human at all.
An experimental treatment made from a plant virus is effective at protecting against a broad range of metastatic cancers in mice, shows a new study from the University of California San Diego.
The joint guideline is designed to help clinicians manage patients who have, or are at risk of developing, glucocorticoid-induced adrenal insufficiency. At least 1% of the global population uses chronic glucocorticoid therapy as anti-inflammatory or immune-suppressive agents.
One of the most common genetic heart diseases worldwide, hypertrophic cardiomyopathy (HCM) causes the walls of the left ventricle to become thick and stiff. In about 70 percent of cases, patients with HCM experience obstruction to blood flow, which increases pressures in the heart and can lead to chest pain, shortness of breath and reduced exercise capacity. While invasive interventions can restore selected patients’ quality of life, pharmacologic therapies that are safe, well-tolerated and that reliably improve how patients feel and function remain an unmet need for patients with obstructive HCM.
Now, a phase 3 trial has shown that a cardiac myosin inhibitor called aficamten enhances exercise capacity in patients with HCM and leads to significant relief in the burden of limiting symptoms, improving the quality of patients' lives